Abstracts tagged "Pulmonary Involvement and Sjogren’s syndrome"

Abstract Number: 2692 • 2016 ACR/ARHP Annual Meeting
Pulmonary Involvement, As Part of the Essdai, in Primary Sjogren’s Syndrome
Anne Heus¹, Suzanne Arends¹, Jolien F. van Nimwegen¹, Alja J. Stel¹, George D. Nossent² and Hendrika Bootsma³, ¹Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ²Pulmonary Medicine and Tuberculosis, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, ³Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, The Netherlands, Groningen, Netherlands
Background/Purpose: In previous studies in primary Sjögren’s syndrome (pSS), the prevalence of pulmonary involvement varied greatly depending on differences in inclusion criteria, imaging modalities and…
Abstract Number: 520 • 2013 ACR/ARHP Annual Meeting
Chronic Obstructive Pulmonary Disease Is Very Common in Primary Sjögren’s Syndrome
Anna M. Nilsson¹, Elke Theander², Roger Hesselstrand³, Eeva Piitulainen⁴, Sandra Diaz⁵, Olle Ekberg⁵, Per Wollmer⁶ and Thomas Mandl⁷, ¹Dept of Rheumatology, Skane University Hospital Malmo, Lund University, Malmo, Sweden, ²Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ³Rheumatology, Lund University, Lund, Sweden, ⁴Dept of Lung medicine, Lund University & Skåne University Hospital, Malmö, Sweden, ⁵Dept of Radiology, Skåne University Hospital Malmo, Lund University, Malmö, Sweden, ⁶Dept of Clinical Physiology, Skane University Hospital Malmo, Lund University, Malmö, Sweden, ⁷Dept of Rheumatology, Skåne University Hospital Malmo, Lund University, Sweden, Malmö, Sweden
Background/Purpose: To study the prevalence of chronic obstructive pulmonary disease (COPD) in patients with primary Sjögren's syndrome (pSS) and its association with respiratory symptoms, pulmonary…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].